title: [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of infliximab administration in refractory uveoretinitis in Behçet's disease (BD).
  
  
  METHODS
  The subjects were 22 consecutive BD patients with refractory uveoretinitis treated with infliximab. Three patients dropped out from the therapy. The other 19 patients received the therapy for 6 months or longer. The efficacy was evaluated by the ocular attacks and best corrected visual acuity at remission in the 19 patients and the safety was evaluated in all 22 patients.
  
  
  RESULTS
  The incidence of ocular attacks in the 6 months before and after the infliximab therapy were 3.0+/-2.6 and 0.4+/-1.1, respectively (p<0.0005). Infliximab was very effective in 7 patients where no ocular attacks occurred throughout infliximab therapy, effective in 10 patients where ocular attacks was reduced, and non-effective in 2 patients. The vision was either improved or unchanged in all eyes at the 6th months therapy. Various adverse effects were seen in 14 patients, but non were serious.
  
  
  CONCLUSIONS
  Infiximab therapy is effective in managing the refractory uveoretinitis in BD, but elucidation of the safety needs more patients and a longer follow-up period.
authors.affiliation: Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Sunao
authors.initials: S
authors.lastname: Sugita
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamada
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Iwanaga
authors.forename: Koju
authors.initials: K
authors.lastname: Kamoi
authors.forename: Mako
authors.initials: M
authors.lastname: Yokota
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takase
authors.forename: Manabu
authors.initials: M
authors.lastname: Mochizuki
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012173:Retinitis / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab